Targeting the checkpoint to kill cancer cells

Biomolecules

Volumn 5, Issue 3, 2015, Pages 1912-1937

  Benada, Jan ^a,b   Macurek, Libor ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

ATM; ATR; Cancer; Checkpoint; Chk1; DNA damage response; Inhibitor; p53; Replication stress; Wee1

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ABEMACICLIB; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CP 466722; CYCLIN DEPENDENT KINASE 2; CYCLIN E; FLAVOPIRIDOL; GEMCITABINE; GSK 2830371; KU 559403; KU 60019; MK 8776; MYC PROTEIN; PALBOCICLIB; PF 00477736; PROTEIN KINASE; PROTEIN P53; RABUSERTIB; RAD51 PROTEIN; RAS PROTEIN; RIBOCICLIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WEE1 KINASE; XL 844; PROTEIN KINASE INHIBITOR;

BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; DNA DAMAGE CHECKPOINT; DNA REPAIR; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CELL CYCLE CHECKPOINT; CELL DEATH; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL DEATH; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84947462513     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5031912     Document Type: Review

References (170)

1. Lukas, J.; Lukas, C.; Bartek, J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat. Cell Biol. 2011, 13, 1161-1169.
2. Medema, R.H.; Macurek, L. Checkpoint control and cancer. Oncogene 2012, 31, 2601-2613.
3. Lemaire, M.; Mondesert, O.; Bugler, B.; Ducommun, B. Ability of human Cdc25B phosphatase splice variants to replace the function of the fission yeast Cdc25 cell cycle regulator. FEMS Yeast Res. 2004, 5, 205-211.
4. Manke, I.A.; Nguyen, A.; Lim, D.; Stewart, M.Q.; Elia, A.E.; Yaffe, M.B. Mapkap kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 2005, 17, 37-48.
5. Uchida, S.; Watanabe, N.; Kudo, Y.; Yoshioka, K.; Matsunaga, T.; Ishizaka, Y.; Nakagama, H.; Poon, R.Y.; Yamashita, K. SCFα(TrCP) mediates stress-activated MAPK-induced Cdc25B degradation. J. Cell Sci. 2011, 124, 2816-2825.
6. Imbriano, C.; Gurtner, A.; Cocchiarella, F.; di Agostino, S.; Basile, V.; Gostissa, M.; Dobbelstein, M.; del Sal, G.; Piaggio, G.; Mantovani, R. Direct P53 transcriptional repression: In vivo analysis of ccaat-containing G2/M promoters. Mol. Cell. Biol. 2005, 25, 3737-3751.
7. McKenzie, L.; King, S.; Marcar, L.; Nicol, S.; Dias, S.S.; Schumm, K.; Robertson, P.; Bourdon, J.C.; Perkins, N.; Fuller-Pace, F.; et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010, 9, 4200-4212.
8. Lord, C.J.; Ashworth, A. The DNA damage response and cancer therapy. Nature 2012, 481, 287-294.
9. Bouwman, P.; Jonkers, J. Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 2014, 20, 540-547.
10. Banerjee, S.; Kaye, S.B.; Ashworth, A. Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 2010, 7, 508-519.
11. Lord, C.J.; Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 2013, 19, 1381-1388.
12. Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434, 864-870.
13. Gorgoulis, V.G.; Vassiliou, L.V.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; Ditullio, R.A., Jr.; Kastrinakis, N.G.; Levy, B.; et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434, 907-913.
14. Castedo, M.; Perfettini, J.L.; Roumier, T.; Andreau, K.; Medema, R.; Kroemer, G. Cell death by mitotic catastrophe: A molecular definition. Oncogene 2004, 23, 2825-2837.
15. Zhou, B.B.; Bartek, J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4, 216-225.
16. Tse, A.N.; Rendahl, K.G.; Sheikh, T.; Cheema, H.; Aardalen, K.; Embry, M.; Ma, S.; Moler, E.J.; Ni, Z.J.; Lopes de Menezes, D.E.; et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin. Cancer Res. 2007, 13, 591-602.
17. Blasina, A.; Hallin, J.; Chen, E.; Arango, M.E.; Kraynov, E.; Register, J.; Grant, S.; Ninkovic, S.; Chen, P.; Nichols, T.; et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 2008, 7, 2394-2404.
18. Zabludoff, S.D.; Deng, C.; Grondine, M.R.; Sheehy, A.M.; Ashwell, S.; Caleb, B.L.; Green, S.; Haye, H.R.; Horn, C.L.; Janetka, J.W.; et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008, 7, 2955-2966.
19. Guzi, T.J.; Paruch, K.; Dwyer, M.P.; Labroli, M.; Shanahan, F.; Davis, N.; Taricani, L.; Wiswell, D.; Seghezzi, W.; Penaflor, E.; et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective Chk1 inhibitor identified via high content screening. Mol. Cancer Ther. 2011, 10, 591-602.
20. Macheret, M.; Halazonetis, T.D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 2015, 10, 425-448.
21. Toledo, L.I.; Altmeyer, M.; Rask, M.B.; Lukas, C.; Larsen, D.H.; Povlsen, L.K.; Bekker-Jensen, S.; Mailand, N.; Bartek, J.; Lukas, J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155, 1088-1103.
22. Sorensen, C.S.; Syljuasen, R.G. Safeguarding genome integrity: The checkpoint kinases ATR, Chk1 and Wee1 restrain Cdk activity during normal DNA replication. Nucleic Acids Res. 2012, 40, 477-486.
23. Petermann, E.; Helleday, T. Pathways of mammalian replication fork restart. Nat. Rev. Mol. Cell Biol. 2010, 11, 683-687.
24. Fugger, K.; Chu, W.K.; Haahr, P.; Kousholt, A.N.; Beck, H.; Payne, M.J.; Hanada, K.; Hickson, I.D.; Sorensen, C.S. FBH1 co-operates with MUS81 in inducing DNA double-strand breaks and cell death following replication stress. Nat. Commun. 2013, doi:10.1038/ncomms2395.
25. Brown, E.J.; Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000, 14, 397-402.
26. Takai, H.; Tominaga, K.; Motoyama, N.; Minamishima, Y.A.; Nagahama, H.; Tsukiyama, T.; Ikeda, K.; Nakayama, K.; Nakanishi, M.; Nakayama, K. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(β/β) mice. Genes Dev. 2000, 14, 1439-1447.
27. Tominaga, Y.; Li, C.; Wang, R.H.; Deng, C.X. Murine WEE1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int. J. Biol. Sci. 2006, 2, 161-170.
28. Montano, R.; Chung, I.; Garner, K.M.; Parry, D.; Eastman, A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol. Cancer Ther. 2012, 11, 427-438.
29. Brooks, K.; Oakes, V.; Edwards, B.; Ranall, M.; Leo, P.; Pavey, S.; Pinder, A.; Beamish, H.; Mukhopadhyay, P.; Lambie, D.; et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 2013, 32, 788-796.
30. Ferrao, P.T.; Bukczynska, E.P.; Johnstone, R.W.; McArthur, G.A. Efficacy of Chk inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012, 31, 1661-1672.
31. Krajewska, M.; Fehrmann, R.S.; Schoonen, P.M.; Labib, S.; de Vries, E.G.; Franke, L.; van Vugt, M.A. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene 2015, 34, 3474-3481.
32. Mak, J.P.; Man, W.Y.; Ma, H.T.; Poon, R.Y. Pharmacological targeting the ATR-Chk1-Wee1 axis involves balancing cell growth stimulation and apoptosis. Oncotarget 2014, 5, 10546-10557.
33. Huertas, P.; Cortes-Ledesma, F.; Sartori, A.A.; Aguilera, A.; Jackson, S.P. Cdk targets SAE2 to control DNA-end resection and homologous recombination. Nature 2008, 455, 689-692.
34. Huertas, P.; Jackson, S.P. Human ctip mediates cell cycle control of DNA end resection and double strand break repair. J. Biol. Chem. 2009, 284, 9558-9565.
35. Sorensen, C.S.; Hansen, L.T.; Dziegielewski, J.; Syljuasen, R.G.; Lundin, C.; Bartek, J.; Helleday, T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 2005, 7, 195-201.
36. Krajewska, M.; Heijink, A.M.; Bisselink, Y.J.; Seinstra, R.I.; Sillje, H.H.; de Vries, E.G.; van Vugt, M.A. Forced activation of Cdk1 via Wee1 inhibition impairs homologous recombination. Oncogene 2013, 32, 3001-3008.
37. Thacker, J. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 2005, 219, 125-135.
38. Paul, A.; Paul, S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Frontiers in bioscience 2014, 19, 605-618.
39. Qiu, L.; Burgess, A.; Fairlie, D.P.; Leonard, H.; Parsons, P.G.; Gabrielli, B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 2000, 11, 2069-2083.
40. Brooks, K.; Ranall, M.; Spoerri, L.; Stevenson, A.; Gunasingh, G.; Pavey, S.; Meunier, F.; Gonda, T.J.; Gabrielli, B. Decatenation checkpoint-defective melanomas are dependent on PI3K for survival. Pigment Cell Melanoma Res. 2014, 27, 813-821.
41. Pavey, S.; Spoerri, L.; Haass, N.K.; Gabrielli, B. DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell Melanoma Res. 2013, 26, 805-816.
42. Grenon, M.; Gilbert, C.; Lowndes, N.F. Checkpoint activation in response to double-strand breaks requires the MRE11/RAD50/XRS2 complex. Nat. Cell Biol. 2001, 3, 844-847.
43. Lee, J.H.; Paull, T.T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007, 26, 7741-7748.
44. Burma, S.; Chen, B.P.; Murphy, M.; Kurimasa, A.; Chen, D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 2001, 276, 42462-42467.
45. Melander, F.; Bekker-Jensen, S.; Falck, J.; Bartek, J.; Mailand, N.; Lukas, J. Phosphorylation of SDT repeats in the MDC1 N terminus triggers retention of NBS1 at the DNA damage-modified chromatin. J. Cell Biol. 2008, 181, 213-226.
46. Ahn, J.Y.; Schwarz, J.K.; Piwnica-Worms, H.; Canman, C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60, 5934-5936.
47. Powell, S.N.; DeFrank, J.S.; Connell, P.; Eogan, M.; Preffer, F.; Dombkowski, D.; Tang, W.; Friend, S. Differential sensitivity of p53(β) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 1995, 55, 1643-1648.
48. Price, B.D.; Youmell, M.B. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996, 56, 246-250.
49. Hickson, I.; Zhao, Y.; Richardson, C.J.; Green, S.J.; Martin, N.M.; Orr, A.I.; Reaper, P.M.; Jackson, S.P.; Curtin, N.J.; Smith, G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004, 64, 9152-9159.
50. Rainey, M.D.; Charlton, M.E.; Stanton, R.V.; Kastan, M.B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008, 68, 7466-7474.
51. Golding, S.E.; Rosenberg, E.; Valerie, N.; Hussaini, I.; Frigerio, M.; Cockcroft, X.F.; Chong, W.Y.; Hummersone, M.; Rigoreau, L.; Menear, K.A.; et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8, 2894-2902.
52. Batey, M.A.; Zhao, Y.; Kyle, S.; Richardson, C.; Slade, A.; Martin, N.M.; Lau, A.; Newell, D.R.; Curtin, N.J. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol. Cancer Ther. 2013, 12, 959-967.
53. Raso, A.; Vecchio, D.; Cappelli, E.; Ropolo, M.; Poggi, A.; Nozza, P.; Biassoni, R.; Mascelli, S.; Capra, V.; Kalfas, F.; et al. Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein. Brain Pathol. 2012, 22, 677-688.
54. Golding, S.E.; Rosenberg, E.; Adams, B.R.; Wignarajah, S.; Beckta, J.M.; O'Connor, M.J.; Valerie, K. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control. Cell Cycle 2012, 11, 1167-1173.
55. Vecchio, D.; Daga, A.; Carra, E.; Marubbi, D.; Baio, G.; Neumaier, C.E.; Vagge, S.; Corvo, R.; Brisigotti, M.P.; Ravetti, J.L.; et al. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019. Int. J. Cancer 2014, 135, 479-491.
56. Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.; Tokarz, M.; Adams, B.R.; Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. Atm kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 2013, 19, 3189-3200.
57. Hoeijmakers, J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411, 366-374.
58. Jazayeri, A.; Falck, J.; Lukas, C.; Bartek, J.; Smith, G.C.; Lukas, J.; Jackson, S.P. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 2006, 8, 37-45.
59. Sartori, A.A.; Lukas, C.; Coates, J.; Mistrik, M.; Fu, S.; Bartek, J.; Baer, R.; Lukas, J.; Jackson, S.P. Human ctip promotes DNA end resection. Nature 2007, 450, 509-514.
60. Kousholt, A.N.; Fugger, K.; Hoffmann, S.; Larsen, B.D.; Menzel, T.; Sartori, A.A.; Sorensen, C.S. CtIP-dependent DNA resection is required for DNA damage checkpoint maintenance but not initiation. J. Cell Biol. 2012, 197, 869-876.
61. Wold, M.S. Replication protein a: A heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. Annu. Rev. Biochem. 1997, 66, 61-92.
62. Cortez, D.; Guntuku, S.; Qin, J.; Elledge, S.J. ATR and ATRIP: Partners in checkpoint signaling. Science 2001, 294, 1713-1716.
63. Cotta-Ramusino, C.; McDonald, E.R., 3rd; Hurov, K.; Sowa, M.E.; Harper, J.W.; Elledge, S.J. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science 2011, 332, 1313-1317.
64. Kumagai, A.; Lee, J.; Yoo, H.Y.; Dunphy, W.G. TopBP1 activates the ATR-ATRIP complex. Cell 2006, 124, 943-955.
65. Delacroix, S.; Wagner, J.M.; Kobayashi, M.; Yamamoto, K.; Karnitz, L.M. The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1. Genes Dev. 2007, 21, 1472-1477.
66. Lee, J.; Kumagai, A.; Dunphy, W.G. The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 with ATR. J. Biol. Chem. 2007, 282, 28036-28044.
67. Wang, J.; Gong, Z.; Chen, J. MDC1 collaborates with TopBP1 in DNA replication checkpoint control. J. Cell Biol. 2011, 193, 267-273.
68. Jeong, S.Y.; Kumagai, A.; Lee, J.; Dunphy, W.G. Phosphorylated claspin interacts with a phosphate-binding site in the kinase domain of Chk1 during ATR-mediated activation. J. Biol. Chem. 2003, 278, 46782-46788.
69. Kumagai, A.; Dunphy, W.G. Repeated phosphopeptide motifs in claspin mediate the regulated binding of Chk1. Nat. Cell Biol. 2003, 5, 161-165.
70. Liu, Q.; Guntuku, S.; Cui, X.S.; Matsuoka, S.; Cortez, D.; Tamai, K.; Luo, G.; Carattini-Rivera, S.; DeMayo, F.; Bradley, A.; et al. Chk1 is an essential kinase that is regulated by ATR and required for the G2/M DNA damage checkpoint. Genes Dev. 2000, 14, 1448-1459.
71. Gilad, O.; Nabet, B.Y.; Ragland, R.L.; Schoppy, D.W.; Smith, K.D.; Durham, A.C.; Brown, E.J. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010, 70, 9693-9702.
72. Murga, M.; Campaner, S.; Lopez-Contreras, A.J.; Toledo, L.I.; Soria, R.; Montaña, M.F.; D'Artista, L.; Schleker, T.; Guerra, C.; Garcia, E.; et al. Exploiting oncogene-induced replicative stress for the selective killing of MYC-driven tumors. Nat. Struct. Mol. Biol. 2011, 18, 1331-1335.
73. Schoppy, D.W.; Ragland, R.L.; Gilad, O.; Shastri, N.; Peters, A.A.; Murga, M.; Fernandez-Capetillo, O.; Diehl, J.A.; Brown, E.J. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Investig. 2012, 122, 241-252.
74. Flynn, R.L.; Cox, K.E.; Jeitany, M.; Wakimoto, H.; Bryll, A.R.; Ganem, N.J.; Bersani, F.; Pineda, J.R.; Suvà, M.L.; Benes, C.H.; et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015, 347, 273-277.
75. Mohni, K.N.; Thompson, P.S.; Luzwick, J.W.; Glick, G.G.; Pendleton, C.S.; Lehmann, B.D.; Pietenpol, J.A.; Cortez, D. A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments. PLoS ONE 2015, 10, e0125482.
76. Sultana, R.; Abdel-Fatah, T.; Perry, C.; Moseley, P.; Albarakti, N.; Mohan, V.; Seedhouse, C.; Chan, S.; Madhusudan, S. Ataxia telangiectasia mutated and RAD3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS ONE 2013, 8, e57098.
77. Charrier, J.D.; Durrant, S.J.; Golec, J.M.; Kay, D.P.; Knegtel, R.M.; MacCormick, S.; Mortimore, M.; O'Donnell, M.E.; Pinder, J.L.; Reaper, P.M.; et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J. Med. Chem. 2011, 54, 2320-2330.
78. Reaper, P.M.; Griffiths, M.R.; Long, J.M.; Charrier, J.D.; Maccormick, S.; Charlton, P.A.; Golec, J.M.; Pollard, J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7, 428-430.
79. Prevo, R.; Fokas, E.; Reaper, P.M.; Charlton, P.A.; Pollard, J.R.; McKenna, W.G.; Muschel, R.J.; Brunner, T.B. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol. Ther. 2012, 13, 1072-1081.
80. Huntoon, C.J.; Flatten, K.S.; Wahner Hendrickson, A.E.; Huehls, A.M.; Sutor, S.L.; Kaufmann, S.H.; Karnitz, L.M. Atr inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013, 73, 3683-3691.
81. Vavrova, J.; Zarybnicka, L.; Lukasova, E.; Rezacova, M.; Novotna, E.; Sinkorova, Z.; Tichy, A.; Pejchal, J.; Durisova, K. Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60). Radiat. Environ. Biophys. 2013, 52, 471-479.
82. Salovska, B.; Fabrik, I.; Durisova, K.; Link, M.; Vavrova, J.; Rezacova, M.; Tichy, A. Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): Phosphoproteomic analysis. Int. J. Mol. Sci. 2014, 15, 12007-12026.
83. Abdel-Fatah, T.M.; Middleton, F.K.; Arora, A.; Agarwal, D.; Chen, T.; Moseley, P.M.; Perry, C.; Doherty, R.; Chan, S.; Green, A.R.; et al. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Mol. Oncol. 2015, 9, 569-585.
84. Fokas, E.; Prevo, R.; Pollard, J.R.; Reaper, P.M.; Charlton, P.A.; Cornelissen, B.; Vallis, K.A.; Hammond, E.M.; Olcina, M.M.; Gillies McKenna, W.; et al. Targeting atr in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012, 3, e441.
85. Hall, A.B.; Newsome, D.; Wang, Y.; Boucher, D.M.; Eustace, B.; Gu, Y.; Hare, B.; Johnson, M.A.; Milton, S.; Murphy, C.E.; et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 2014, 5, 5674-5685.
86. Foote, K.M.; Blades, K.; Cronin, A.; Fillery, S.; Guichard, S.S.; Hassall, L.; Hickson, I.; Jacq, X.; Jewsbury, P.J.; McGuire, T.M.; et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1- (methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J. Med. Chem. 2013, 56, 2125-2138.
87. Guichard, S.M.; Brown, E.; Odedra, R.; Hughes, A.; Heathcote, D.; Barnes, J.; Lau, A.; Powell, S.; Jones, C.D.; Nissink, W.; et al. The pre-clinical in vitro and in vivo activity of AZD6738: A potent and selective inhibitor of ATR kinase. Cancer Res. 2013, doi:10.1158/1538-7445.AM2013-3343.
88. Liu, Y.; Vidanes, G.; Lin, Y.C.; Mori, S.; Siede, W. Characterization of a Saccharomyces cerevisiae homologue of Schizosaccharomyces pombe Chk1 involved in DNA-damage-induced M-phase arrest. Mol. Gen. Genet. 2000, 262, 1132-1146.
89. Okita, N.; Minato, S.; Ohmi, E.; Tanuma, S.; Higami, Y. DNA damage-induced Chk1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism. FEBS Lett. 2012, 586, 3974-3979.
90. Kasahara, K.; Goto, H.; Enomoto, M.; Tomono, Y.; Kiyono, T.; Inagaki, M. 14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J. 2010, 29, 2802-2812.
91. Busino, L.; Donzelli, M.; Chiesa, M.; Guardavaccaro, D.; Ganoth, D.; Dorrello, N.V.; Hershko, A.; Pagano, M.; Draetta, G.F. Degradation of Cdc25A by beta-TRCP during S phase and in response to DNA damage. Nature 2003, 426, 87-91.
92. Jin, J.; Shirogane, T.; Xu, L.; Nalepa, G.; Qin, J.; Elledge, S.J.; Harper, J.W. Scfbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 2003, 17, 3062-3074.
93. Forrest, A.; Gabrielli, B. Cdc25B activity is regulated by 14-3-3. Oncogene 2001, 20, 4393-4401.
94. Graves, P.R.; Lovly, C.M.; Uy, G.L.; Piwnica-Worms, H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 2001, 20, 1839-1851.
95. Schwarz, J.K.; Lovly, C.M.; Piwnica-Worms, H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 2003, 1, 598-609.
96. Jack, M.T.; Woo, R.A.; Hirao, A.; Cheung, A.; Mak, T.W.; Lee, P.W. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc. Natl. Acad. Sci. USA 2002, 99, 9825-9829.
97. Ma, C.X.; Janetka, J.W.; Piwnica-Worms, H. Death by releasing the breaks: Chk1 inhibitors as cancer therapeutics. Trends Mol. Med. 2011, 17, 88-96.
98. Reinhardt, H.C.; Aslanian, A.S.; Lees, J.A.; Yaffe, M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007, 11, 175-189.
99. Bunch, R.T.; Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 1996, 2, 791-797.
100. Tse, A.N.; Schwartz, G.K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 2004, 64, 6635-6644.
101. Fuse, E.; Tanii, H.; Kurata, N.; Kobayashi, H.; Shimada, Y.; Tamura, T.; Sasaki, Y.; Tanigawara, Y.; Lush, R.D.; Headlee, D.; et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 1998, 58, 3248-3253.
102. Kortmansky, J.; Shah, M.A.; Kaubisch, A.; Weyerbacher, A.; Yi, S.; Tong, W.; Sowers, R.; Gonen, M.; O'Reilly, E.; Kemeny, N.; et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J. Clin. Oncol. 2005, 23, 1875-1884.
103. Dent, P.; Tang, Y.; Yacoub, A.; Dai, Y.; Fisher, P.B.; Grant, S. Chk1 inhibitors in combination chemotherapy: Thinking beyond the cell cycle. Mol. Interv. 2011, 11, 133-140.
104. Matthews, D.J.; Yakes, F.M.; Chen, J.; Tadano, M.; Bornheim, L.; Clary, D.O.; Tai, A.; Wagner, J.M.; Miller, N.; Kim, Y.D.; et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007, 6, 104-110.
105. Sausville, E.; Lorusso, P.; Carducci, M.; Carter, J.; Quinn, M.F.; Malburg, L.; Azad, N.; Cosgrove, D.; Knight, R.; Barker, P.; et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014, 73, 539-549.
106. Weiss, G.J.; Donehower, R.C.; Iyengar, T.; Ramanathan, R.K.; Lewandowski, K.; Westin, E.; Hurt, K.; Hynes, S.M.; Anthony, S.P.; McKane, S. Phase I dose-escalation study to examine the safety and tolerability of ly2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer. Investig. New Drug 2013, 31, 136-144.
107. King, C.; Diaz, H.; Barnard, D.; Barda, D.; Clawson, D.; Blosser, W.; Cox, K.; Guo, S.; Marshall, M. Characterization and preclinical development of ly2603618: A selective and potent Chk1 inhibitor. Investig. New Drugs 2014, 32, 213-226.
108. Calvo, E.; Chen, V.; Marshall, M.; Ohnmacht, U.; Hynes, S.; Kumm, E.; Diaz, H.B.; Barnard, D.; Merzoug, F.; Huber, L.; et al. Preclinical analyses and phase I evaluation of ly2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Investig. New Drug 2014, 32, 955-968.
109. Daud, A.I.; Ashworth, M.T.; Strosberg, J.; Goldman, J.W.; Mendelson, D.; Springett, G.; Venook, A.P.; Loechner, S.; Rosen, L.S.; Shanahan, F.; et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J. Clin. Oncol. 2015, 33, 1060-1066.
110. Watanabe, N.; Broome, M.; Hunter, T. Regulation of the human WEE1HU Cdk tyrosine 15-kinase during the cell cycle. EMBO J. 1995, 14, 1878-1891.
111. Watanabe, N.; Arai, H.; Nishihara, Y.; Taniguchi, M.; Watanabe, N.; Hunter, T.; Osada, H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFα-TrCP. Proc. Natl. Acad. Sci. USA 2004, 101, 4419-4424.
112. Lee, J.; Kumagai, A.; Dunphy, W.G. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol. Biol. Cell 2001, 12, 551-563.
113. Parker, L.L.; Piwnica-Worms, H. Inactivation of the p34Cdc2-cyclin B complex by the human Wee1 tyrosine kinase. Science 1992, 257, 1955-1957.
114. Saini, P.; Li, Y.; Dobbelstein, M. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Oncotarget 2015, 6, 13072-13087.
115. Panek, R.L.; Lu, G.H.; Klutchko, S.R.; Batley, B.L.; Dahring, T.K.; Hamby, J.M.; Hallak, H.; Doherty, A.M.; Keiser, J.A. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 1997, 283, 1433-1444.
116. Wang, Y.; Li, J.; Booher, R.N.; Kraker, A.; Lawrence, T.; Leopold, W.R.; Sun, Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001, 61, 8211-8217.
117. Palmer, B.D.; Thompson, A.M.; Booth, R.J.; Dobrusin, E.M.; Kraker, A.J.; Lee, H.H.; Lunney, E.A.; Mitchell, L.H.; Ortwine, D.F.; Smaill, J.B.; et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J. Med. Chem. 2006, 49, 4896-4911.
118. Arora, S.; Bisanz, K.M.; Peralta, L.A.; Basu, G.D.; Choudhary, A.; Tibes, R.; Azorsa, D.O. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol. Oncol. 2010, 118, 220-227.
119. Hirai, H.; Iwasawa, Y.; Okada, M.; Arai, T.; Nishibata, T.; Kobayashi, M.; Kimura, T.; Kaneko, N.; Ohtani, J.; Yamanaka, K.; et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 2009, 8, 2992-3000.
120. Mizuarai, S.; Yamanaka, K.; Itadani, H.; Arai, T.; Nishibata, T.; Hirai, H.; Kotani, H. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol. Cancer 2009, 8, 34.
121. Hirai, H.; Arai, T.; Okada, M.; Nishibata, T.; Kobayashi, M.; Sakai, N.; Imagaki, K.; Ohtani, J.; Sakai, T.; Yoshizumi, T.; et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010, 9, 514-522.
122. Bridges, K.A.; Hirai, H.; Buser, C.A.; Brooks, C.; Liu, H.; Buchholz, T.A.; Molkentine, J.M.; Mason, K.A.; Meyn, R.E. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res. 2011, 17, 5638-5648.
123. Rajeshkumar, N.V.; de Oliveira, E.; Ottenhof, N.; Watters, J.; Brooks, D.; Demuth, T.; Shumway, S.D.; Mizuarai, S.; Hirai, H.; Maitra, A.; et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res. 2011, 17, 2799-2806.
124. Do, K.; Wilsker, D.; Ji, J.; Zlott, J.; Freshwater, T.; Kinders, R.J.; Collins, J.; Chen, A.P.; Doroshow, J.H.; Kummar, S. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J. Clin. Oncol. 2015, doi:10.1200/JCO.2014.60.4009.
125. Carrassa, L.; Chila, R.; Lupi, M.; Ricci, F.; Celenza, C.; Mazzoletti, M.; Broggini, M.; Damia, G. Combined inhibition of chk1 and wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012, 11, 2507-2517.
126. Russell, M.R.; Levin, K.; Rader, J.; Belcastro, L.; Li, Y.; Martinez, D.; Pawel, B.; Shumway, S.D.; Maris, J.M.; Cole, K.A. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res. 2013, 73, 776-784.
127. Chila, R.; Basana, A.; Lupi, M.; Guffanti, F.; Gaudio, E.; Rinaldi, A.; Cascione, L.; Restelli, V.; Tarantelli, C.; Bertoni, F.; et al. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget 2015, 6, 3394-3408.
128. Magnussen, G.I.; Emilsen, E.; Giller Fleten, K.; Engesaeter, B.; Nahse-Kumpf, V.; Fjaer, R.; Slipicevic, A.; Florenes, V.A. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer 2015, doi:10.1186/s12885-015-1474-8.
129. Raman, M.; Earnest, S.; Zhang, K.; Zhao, Y.; Cobb, M.H. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J. 2007, 26, 2005-2014.
130. Brancho, D.; Tanaka, N.; Jaeschke, A.; Ventura, J.J.; Kelkar, N.; Tanaka, Y.; Kyuuma, M.; Takeshita, T.; Flavell, R.A.; Davis, R.J. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003, 17, 1969-1978.
131. Ben-Levy, R.; Leighton, I.A.; Doza, Y.N.; Attwood, P.; Morrice, N.; Marshall, C.J.; Cohen, P. Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J. 1995, 14, 5920-5930.
132. Reinhardt, H.C.; Hasskamp, P.; Schmedding, I.; Morandell, S.; van Vugt, M.A.; Wang, X.; Linding, R.; Ong, S.E.; Weaver, D.; Carr, S.A.; et al. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol. Cell 2010, 40, 34-49.
133. Morandell, S.; Reinhardt, H.C.; Cannell, I.G.; Kim, J.S.; Ruf, D.M.; Mitra, T.; Couvillon, A.D.; Jacks, T.; Yaffe, M.B. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep. 2013, 5, 868-877.
134. Dietlein, F.; Kalb, B.; Jokic, M.; Noll, E.M.; Strong, A.; Tharun, L.; Ozretic, L.; Kunstlinger, H.; Kambartel, K.; Randerath, W.J.; et al. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell 2015, 162, 146-159.
135. Petitjean, A.; Achatz, M.I.; Borresen-Dale, A.L.; Hainaut, P.; Olivier, M. Tp53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26, 2157-2165.
136. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445, 661-665.
137. Khoo, K.H.; Verma, C.S.; Lane, D.P. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014, 13, 217-236.
138. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
139. Chen, L.; Rousseau, R.F.; Middleton, S.A.; Nichols, G.L.; Newell, D.R.; Lunec, J.; Tweddle, D.A. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget 2015, 6, 10207-10221.
140. Ding, Q.; Zhang, Z.; Liu, J.J.; Jiang, N.; Zhang, J.; Ross, T.M.; Chu, X.J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 2013, 56, 5979-5983.
141. Higgins, B.; Glenn, K.; Walz, A.; Tovar, C.; Filipovic, Z.; Hussain, S.; Lee, E.; Kolinsky, K.; Tannu, S.; Adames, V.; et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin. Cancer Res. 2014, 20, 3742-3752.
142. Bulavin, D.V.; Phillips, C.; Nannenga, B.; Timofeev, O.; Donehower, L.A.; Anderson, C.W.; Appella, E.; Fornace, A.J., Jr. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(INK4A)-p19(ARF) pathway. Nat. Genet. 2004, 36, 343-350.
143. Demidov, O.N.; Timofeev, O.; Lwin, H.N.; Kek, C.; Appella, E.; Bulavin, D.V. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 2007, 1, 180-190.
144. Saito-Ohara, F.; Imoto, I.; Inoue, J.; Hosoi, H.; Nakagawara, A.; Sugimoto, T.; Inazawa, J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003, 63, 1876-1883.
145. Wang, P.; Rao, J.; Yang, H.; Zhao, H.; Yang, L. Ppm1d silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells. J. Huazhong Univ. Sci. Technol. 2011, 31, 94-99.
146. Gilmartin, A.G.; Faitg, T.H.; Richter, M.; Groy, A.; Seefeld, M.A.; Darcy, M.G.; Peng, X.; Federowicz, K.; Yang, J.; Zhang, S.Y.; et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat. Chem. Biol. 2014, 10, 181-187.
147. Richter, M.; Dayaram, T.; Gilmartin, A.G.; Ganji, G.; Pemmasani, S.K.; van der Key, H.; Shohet, J.M.; Donehower, L.A.; Kumar, R. Wip1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One 2015, 10, e0115635.
148. Emelyanov, A.; Bulavin, D.V. Wip1 phosphatase in breast cancer. Oncogene 2014, doi:10.1038/onc.2014.375.
149. Kleiblova, P.; Shaltiel, I.A.; Benada, J.; Sevcik, J.; Pechackova, S.; Pohlreich, P.; Voest, E.E.; Dundr, P.; Bartek, J.; Kleibl, Z.; et al. Gain-of-function mutations of Ppm1d/Wip1 impair the p53-dependent g1 checkpoint. J. Cell Biol. 2013, 201, 511-521.
150. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8, 547-566.
151. Malumbres, M.; Barbacid, M. Cell cycle, Cdks and cancer: A changing paradigm. Nat. Rev. Cancer 2009, 9, 153-166.
152. Yu, Q.; Geng, Y.; Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411, 1017-1021.
153. Landis, M.W.; Pawlyk, B.S.; Li, T.; Sicinski, P.; Hinds, P.W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006, 9, 13-22.
154. Puyol, M.; Martin, A.; Dubus, P.; Mulero, F.; Pizcueta, P.; Khan, G.; Guerra, C.; Santamaria, D.; Barbacid, M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18, 63-73.
155. Sicinska, E.; Aifantis, I.; Le Cam, L.; Swat, W.; Borowski, C.; Yu, Q.; Ferrando, A.A.; Levin, S.D.; Geng, Y.; von Boehmer, H.; et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 2003, 4, 451-461.
156. Schmitz, R.; Young, R.M.; Ceribelli, M.; Jhavar, S.; Xiao, W.; Zhang, M.; Wright, G.; Shaffer, A.L.; Hodson, D.J.; Buras, E.; et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490, 116-120.
157. Monahan, K.B.; Rozenberg, G.I.; Krishnamurthy, J.; Johnson, S.M.; Liu, W.; Bradford, M.K.; Horner, J.; Depinho, R.A.; Sharpless, N.E. Somatic p16(Ink4A) loss accelerates melanomagenesis. Oncogene 2010, 29, 5809-5817.
158. Curtin, J.A.; Fridlyand, J.; Kageshita, T.; Patel, H.N.; Busam, K.J.; Kutzner, H.; Cho, K.H.; Aiba, S.; Brocker, E.B.; LeBoit, P.E.; et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353, 2135-2147.
159. Smalley, K.S.; Lioni, M.; Dalla Palma, M.; Xiao, M.; Desai, B.; Egyhazi, S.; Hansson, J.; Wu, H.; King, A.J.; van Belle, P.; et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 2008, 7, 2876-2883.
160. Arguello, F.; Alexander, M.; Sterry, J.A.; Tudor, G.; Smith, E.M.; Kalavar, N.T.; Greene, J.F., Jr.; Koss, W.; Morgan, C.D.; Stinson, S.F.; et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998, 91, 2482-2490.
161. Parker, B.W.; Kaur, G.; Nieves-Neira, W.; Taimi, M.; Kohlhagen, G.; Shimizu, T.; Losiewicz, M.D.; Pommier, Y.; Sausville, E.A.; Senderowicz, A.M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998, 91, 458-465.
162. Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, p276-00. Mol. Cancer Ther. 2007, 6, 918-925.
163. Finn, R.S.; Dering, J.; Conklin, D.; Kalous, O.; Cohen, D.J.; Desai, A.J.; Ginther, C.; Atefi, M.; Chen, I.; Fowst, C.; et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, doi:10.1186/bcr2419.
164. Choi, Y.J.; Li, X.; Hydbring, P.; Sanda, T.; Stefano, J.; Christie, A.L.; Signoretti, S.; Look, A.T.; Kung, A.L.; von Boehmer, H.; et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012, 22, 438-451.
165. Sawai, C.M.; Freund, J.; Oh, P.; Ndiaye-Lobry, D.; Bretz, J.C.; Strikoudis, A.; Genesca, L.; Trimarchi, T.; Kelliher, M.A.; Clark, M.; et al. Therapeutic targeting of the cyclin D3:Cdk4/6 complex in T cell leukemia. Cancer Cell 2012, 22, 452-465.
166. Leonard, J.P.; LaCasce, A.S.; Smith, M.R.; Noy, A.; Chirieac, L.R.; Rodig, S.J.; Yu, J.Q.; Vallabhajosula, S.; Schoder, H.; English, P.; et al. Selective Cdk4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012, 119, 4597-4607.
167. Murphy, C.G.; Dickler, M.N. The role of Cdk4/6 inhibition in breast cancer. Oncologist 2015, 20, 483-490.
168. Anders, L.; Ke, N.; Hydbring, P.; Choi, Y.J.; Widlund, H.R.; Chick, J.M.; Zhai, H.; Vidal, M.; Gygi, S.P.; Braun, P.; et al. A systematic screen for Cdk4/6 substrates links foxm1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20, 620-634.
169. Yadav, V.; Chen, S.H.; Yue, Y.G.; Buchanan, S.; Beckmann, R.P.; Peng, S.B. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacol. Ther. 2015, 149, 139-149.
170. Derenzini, E.; Agostinelli, C.; Imbrogno, E.; Iacobucci, I.; Casadei, B.; Brighenti, E.; Righi, S.; Fuligni, F.; di Rora, A.G.L.; Ferrari, A.; et al. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 2015, 6, 6553-6569.